AI Article Synopsis
- Hypoxia plays a crucial role in cancer as it's linked to tumor growth, spread, recurrence, and treatment responses.
- Current methods for measuring tumor oxygen levels are inadequate, highlighting the need for effective non-invasive techniques.
- Fluorine-19 MRI and spectroscopy offer promising advancements for monitoring oxygen levels in tumors, potentially improving treatment planning and assessment.
Article Abstract
Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11307-021-01648-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!